Clinical Trials Browser

Phase 1 × INDUSTRY × DS-8273a × Clear all

NCT02076451 2019-02-12

Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1 Completed

Lymphoma

NCT02991196 2019-02-12

Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Phase 1 Terminated

Gastrointestinal

Colorectal Neoplasms